Collaborations & Alliances

BMS, Apexigen in Opdivo Clinical Collaboration

Will evaluate BMS’ Opdivo with Apexigen’s APX005M in patients with advanced solid tumors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb Co. and Apexigen, Inc. have entered a clinical trial collaboration to evaluate BMS’ Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors. APX005M is an investigational compound designed to activate CD40, a key immune co-stimulatory receptor essential to regulating the activation of immune responses against cancer.   The companies will evaluate the safety, tolerability and preliminary efficacy of APX005M in combination with Opdivo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters